A landmark clinical trial has demonstrated that CRISPR gene therapy offers transformative potential for children suffering from sickle cell disease and beta-thalassemia. The therapy, called exagamglogene autotemcel (exa-cel), works by editing patients’ own bone marrow cells to produce functional hemoglobin, effectively addressing the root cause of these inherited blood disorders.
Published in The New England Journal of Medicine, the phase 3 trial enrolled 44 children aged 12-17 across multiple countries. Results showed that 42 of 44 patients achieved transfusion independence within 12 months of treatment, with clinical benefits sustained beyond this period. The manageable safety profile, with no treatment-related deaths reported in the pediatric cohort, further supports the therapy’s viability.
This breakthrough represents a paradigm shift in hemoglobinopathy management, offering hope to hundreds of thousands of children worldwide who currently depend on lifelong transfusions. The sustained efficacy and safety outcomes position exa-cel as a potential cure rather than merely a management strategy.
Read the full article on GMJ Newsroom.
Was this article helpful?
